Ascletis’s daily acne tablet set for China review after Phase III win
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals.
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals.
What's Your Reaction?
